News

Niclosamide, an oral medication widely used to eradicate tapeworm infections, may have the potential to slow disease progression in Parkinson’s patients with mutations in the PINK1 gene, researchers report. Their study, “The Anthelmintic Drug Niclosamide and its Analogues Activate the Parkinson’s Disease Associated Protein Kinase PINK1,” was…

Researchers have uncovered how aggregates of the Parkinson’s disease-associated protein alpha-synuclein damages nerve cells. The discovery offers scientists a road map to strategies for developing new treatments for the disease. The study is also a breakthrough in Parkinson’s research. Even though researchers have long known that alpha-synuclein protein…

The U.S. Food and Drug Administration has approved Boston Scientific’s Vercise Deep Brain Stimulation system to help Parkinson’s patients control their movement. Europe and Australia have already approved the system — the first to target specific nerve cells in the brain. It does this by stimulating electrodes that surgeons…